Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Sells $93,575.04 in Stock

Tyra Biosciences, Inc. (NASDAQ:TYRA - Get Free Report) Director Gilla Kaplan sold 9,568 shares of the company's stock in a transaction dated Wednesday, June 18th. The stock was sold at an average price of $9.78, for a total transaction of $93,575.04. Following the completion of the transaction, the director now owns 28,231 shares in the company, valued at approximately $276,099.18. The trade was a 25.31% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Gilla Kaplan also recently made the following trade(s):

• On Tuesday, June 17th, Gilla Kaplan sold 10 shares of Tyra Biosciences stock. The shares were sold at an average price of $10.35, for a total transaction of $103.50.
• On Monday, June 16th, Gilla Kaplan sold 6,814 shares of Tyra Biosciences stock. The shares were sold at an average price of $10.38, for a total transaction of $70,729.32.
• On Friday, June 13th, Gilla Kaplan sold 15,000 shares of Tyra Biosciences stock. The stock was sold at an average price of $10.31, for a total transaction of $154,650.00.
• On Thursday, June 12th, Gilla Kaplan sold 30,000 shares of Tyra Biosciences stock. The stock was sold at an average price of $10.31, for a total transaction of $309,300.00.

Tyra Biosciences Trading Down 2.8%

Tyra Biosciences stock traded down $0.27 during midday trading on Friday, hitting $9.23. The stock had a trading volume of 486,061 shares, compared to its average volume of 281,309. Tyra Biosciences, Inc. has a 52-week low of $6.42 and a 52-week high of $29.60. The firm's fifty day moving average is $9.76 and its two-hundred day moving average is $11.77. The company has a market capitalization of $490.02 million, a PE ratio of -5.66 and a beta of 1.07.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.49) by $0.02. As a group, equities research analysts predict that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Tyra Biosciences

A number of institutional investors have recently added to or reduced their stakes in TYRA. KLP Kapitalforvaltning AS purchased a new stake in Tyra Biosciences during the 4th quarter valued at approximately $31,000. US Bancorp DE purchased a new position in shares of Tyra Biosciences in the fourth quarter valued at $50,000. BNP Paribas Financial Markets purchased a new position in shares of Tyra Biosciences in the fourth quarter valued at $60,000. Aquatic Capital Management LLC purchased a new position in shares of Tyra Biosciences in the fourth quarter valued at $64,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Tyra Biosciences in the first quarter valued at $84,000. 84.14% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on TYRA shares. Wedbush reiterated an "outperform" rating and issued a $30.00 price objective on shares of Tyra Biosciences in a research note on Friday, March 28th. HC Wainwright reiterated a "buy" rating and issued a $30.00 price objective on shares of Tyra Biosciences in a research note on Monday, March 31st. Finally, Piper Sandler started coverage on shares of Tyra Biosciences in a report on Wednesday, May 21st. They issued an "overweight" rating and a $33.00 target price for the company. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $30.83.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.